New combo for untreated follicular lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of targeted drugs (zanubrutinib, lenalidomide, and rituximab) against a standard two-drug combination for people with newly diagnosed follicular lymphoma who need treatment right away. It aims to see if the three-drug combo is more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are newly diagnosed with follicular lymphoma (grade 1, 2, or 3a) and have not had any prior treatment for it.
- Your doctor has determined you need to start treatment soon because of symptoms like large lymph nodes, fever, or night sweats.
- You have at least one measurable tumor or lymph node on a CT or PET scan.
- You are 18 years or older and have a good performance status (able to do most daily activities).
- Your blood counts, liver, kidney, and heart function are within acceptable limits (your doctor will check this).
- You agree to use effective birth control if you could become pregnant or get someone pregnant, and you do not have a history of blood clots or severe allergies to the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three targeted drugs (zanubrutinib, rituximab, lenalidomide) plus an immunotherapy drug (tislelizumab) for people with follicular lymphoma that has returned or not responded to at least two prior treatments. The goal is to see if this combination is safe and effective.
This trial tests a combination of three targeted drugs (zanubrutinib, rituximab, and venetoclax) for people with untreated follicular lymphoma. The goal is to see if this combination works better than standard treatments and has manageable side effects.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) for people with a specific high-risk form of follicular lymphoma who have not yet been treated. The goal is to see if this combination can control the lymphoma more effectively.
This trial tests a new combination of three targeted drugs (Orelabrutinib, Obinutuzumab, and Lenalidomide) against the standard approach for people with follicular lymphoma who haven't been treated yet. The goal is to see if the new drug combo works better and is safe.
This trial tests a combination of targeted therapy (zanubrutinib) and chemotherapy (G-CHOP) in people with newly diagnosed, intermediate-high risk follicular lymphoma that has not yet been treated. The goal is to see if this combination works better than current standard treatments.
Hear when a new Follicular Lymphomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.